Affordable Access

deepdyve-link
Publisher Website

[Place of autologous and allogeneic hematopoietic stem cell transplantation in ovarian cancer].

Authors
  • Nayl, B
  • Cabrespine-Faugeras, A
  • Maliki, Ym
  • Bay, J-O
Type
Published Article
Journal
Bulletin du Cancer
Publisher
Elsevier
Publication Date
Dec 01, 2009
Volume
96
Issue
12
Pages
1225–1232
Identifiers
DOI: 10.1684/bdc.2009.1004
PMID: 19939780
Source
Medline
License
Unknown

Abstract

For several years, research for treatment of advanced ovarian cancer in first line or in relapse was made on the basis of two concepts. The first one is to improve the response rate by increasing the dose of chemotherapy delivered by high dose chemotherapy consolidation. The second concept is the development of an immunological antitumoral effect following allogeneic hematopoietic stem cells transplantation (HSC). The autologous HSC transplantation is required to first concept because of medullar toxicities induced by high dose chemotherapy. This therapeutic was widely studied in first line of advanced ovarian cancer. The recent phases III demonstrate an increase of the toxicity without efficacy improvement compared with the standard doses of chemotherapy. In relapse, the response rate is improved but an important toxicity is observed with low response duration. Evaluation of high dose of topotecan in association with the carboplatine is currently on going. Allogeneic HSC transplantation presents a potential interest because of immunogeneic control against tumour. However, the direct proof of immunotherapy efficacy on OC in a clinical study is still missing, toxicities should not be disregarded.

Report this publication

Statistics

Seen <100 times